GSK
-
【Product for Licensing】T-cell engager (TCE), bispecific, trispecific, and multispecific products are available
If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap. Many thanks!~
-
GSK终止乙肝疫苗二期临床
扫码报名2024肝病新药联盟年会暨减重新药论坛！ 2024年12月3日，行业知名媒体《Endpoints News》报道称，GSK终止了其在研治疗性乙肝（HBV）疫苗GSK3528…
-
【快讯】6.5亿美元！GSK与Flagship孵化的Vesalius达成多靶点战略联盟，为帕金森病患者开发突破性疗法
药时代热烈祝贺GSK和Vesalius Therapeutics！
-
GSK and Vesalius Enter Multi-Target Strategic Alliance to Develop Breakthrough Treatments for People Afflicted with Parkinson’s Disease
Congratulations to GSK and Vesalius Therapeutics!
-
GSK exits BIO
GSK remains a member of PhRMA (Pharmaceutical Research and Manufacturers of America), the industry association representing large pharmaceutical companies
-
GSK退出BIO
2024年10月8日，知名行业媒体Endpoints News报道称，GSK将退出BIO（生物技术创新组织）。该消息经GSK的一位发言人证实，并表示GSK仍是代表大型制药公司的行业…
-
GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
Congratulations to Chimagen and GSK!
-
Split! Sanofi may book $16.4 billion
For more reports, please follow DrugTimes. Many thanks!
-
In four months, Sanofi lost $80 million, but it’s worth it
Drug discovery and development is not easy. We pay respect to all the heroes
